Beyond the Heartbeat: A $39M Bid to End a 50-Year Crisis in Childbirth

PITTSBURGH, PA – June 24, 2026

The rhythmic beep of the fetal heart rate monitor is the soundtrack to modern childbirth. For countless expectant parents, it is a source of reassurance—a steady signal of the life about to enter the world. But for clinicians, and for a growing number of families left with more questions than answers, that sound is often a symphony of ambiguity. The technology at its core, largely unchanged since the 1970s, has become a central figure in a silent crisis—one that contributes to the United States having the highest maternal mortality rate among wealthy nations and a Cesarean section rate that experts agree is dangerously high.

Now, a team of scientists and engineers, led by Carnegie Mellon University, is attempting to rewrite that soundtrack. With an award of up to $39.3 million from the Advanced Research Projects Agency for Health (ARPA-H), they are developing a system designed not just to listen to the heart, but to understand the fundamental well-being of a fetus in real time. The project, called OMEGA, represents a high-stakes bet that technology can solve a problem that has perplexed medicine for half a century: how to know, with certainty, if a baby is safe.

The Fifty-Year-Old Dilemma

To understand the promise of OMEGA, one must first grasp the profound limitations of what it aims to replace. Current electronic fetal monitoring tracks a baby’s heart rate in relation to the mother’s contractions. An unusual pattern can signal “fetal distress,” a vague but terrifying term that often triggers a cascade of interventions, culminating in a C-section. The problem is, the monitor is notoriously unreliable. Studies have shown its false-positive rate for predicting certain severe neurological injuries can be as high as 99.8%. It frequently suggests a crisis where none exists.

This unreliability has staggering consequences. Roughly one-third of all births in the U.S. are via C-section, a major abdominal surgery with risks of hemorrhage, infection, and complications in future pregnancies. While life-saving when necessary, the World Health Organization warns that rates above 15% do not improve maternal or infant mortality. Many of these surgeries are performed for “non-reassuring fetal status,” a diagnosis based on the very data we know to be flawed.

“Clinicians often have to make difficult decisions with incomplete and unreliable data during childbirth,” explained Dr. Hyagriv Simhan, an OB/GYN at UPMC Magee-Womens Hospital, a partner on the project. This gap in knowledge creates a climate of defensive medicine, where the fear of litigation can push doctors toward surgical intervention.

For parents, the experience is one of uncertainty and fear. An alarming monitor can transform the hopeful anticipation of labor into a high-stress medical emergency, sometimes unnecessarily. The system that was meant to provide a window into the womb has, for many, become a clouded pane of glass.

A Technological Leap of Faith

The OMEGA system—short for Optical, Mechanical, and Electrical Global Assessment of fetal hypoxia—is a radical departure from the status quo. Instead of interpreting the shadows of heart rate patterns, it aims to measure the one thing that truly matters: oxygen. Fetal hypoxia, or a lack of oxygen, is the root cause of most genuine distress during labor. The OMEGA wearable, a noninvasive band, will use a sophisticated suite of sensors to measure it directly.

“When a fetus is suspected to be hypoxic, care teams may have to act quickly without knowing the underlying cause,” said Jana Kainerstorfer, Professor of Biomedical Engineering at Carnegie Mellon and the project’s Principal Investigator. “The ability to directly measure a lack of oxygen to the fetus, and identify the cause, will have significant implications.”

At its heart is an optical system that uses light to peer through the mother’s abdomen and measure the oxygen saturation in the baby’s blood—a technique Kainerstorfer’s lab has spent years perfecting for deep-tissue analysis. This is combined with mechanical sensors that precisely track uterine contractions and electrical sensors that monitor physiological responses. By integrating these data streams, OMEGA isn’t just asking if the baby is in trouble; it’s asking why, by assessing the entire system of mother, placenta, and fetus.

“From a technology standpoint, the question is always the same, how do you measure physiology deep inside tissue you can’t directly access?” Kainerstorfer concluded. The challenge is immense, requiring algorithms that can filter out the “noise” from the mother’s own body to isolate the baby’s faint signal. But the collaborative team, which includes experts from nine institutions like the Children’s Hospital of Philadelphia (CHOP) and the University of Pittsburgh, believes it is a solvable problem.

A National Imperative for Safer Births

The fact that this project is funded by ARPA-H is itself significant. The agency was created to swing for the fences—to fund high-risk, high-reward “moonshot” projects that could fundamentally change American healthcare. OMEGA is a cornerstone of ARPA-H’s ‘Making Obstetric Care Smart’ program, a direct response to the nation’s dismal maternal health outcomes.

This isn't just about a fancy new gadget. It’s about providing actionable intelligence in a high-stakes environment. It’s about empowering doctors to make better decisions, giving mothers more agency and mobility during labor, and preventing the trauma and physical cost of unnecessary surgeries. It’s about restoring clarity and confidence to one of life’s most profound experiences.

“This project is a chance to close the gap between what clinicians need – reliable, real-time clarity – and what current monitoring can provide,” said Tiffany Ko, a co-leader on the project from CHOP. “Our team is focused on methods that are rigorous, interpretable, and built for the realities of the delivery room.”

The road from a promising prototype to a ubiquitous tool in every hospital is long and fraught with challenges. But for the first time in a generation, there is a credible, well-funded effort to move beyond the ambiguous rhythm of the fetal heartbeat. The goal is to replace it with a clear, direct, and life-sustaining signal of truth.

If we can provide clinicians with better information about fetal oxygenation, that would be a meaningful step forward for maternal and fetal care.